Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Protein Implicated in Aberrant B-cell Survival in Transplant Disease

By BiotechDaily International staff writers
Posted on 27 Aug 2012
Ex vivo study finds that B-cells from patients with chronic graft vs. host disease (cGVHD) are in a heightened metabolic state and are resistant to apoptosis compared to patients without cGVHD, and leads to identification of a key candidate target for development of more effective drug therapies.

The research team, primarily from University of North Carolina’s Lineberger Comprehensive Cancer Center (UNC Lineberger; Chapel Hill, NC, USA), performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than one year from the time of allogeneic hematopoietic stem cell (HSCT) transplantation. In addition to the finding of the aberrantly sustained activation of the B-cells from patients with cGVHD, an investigation into the mechanisms involved in this process led to the implication of a mechanistic link between this abnormal B-cell survival and the TNF family member signaling protein called BAFF, thus identifying BAFF as having an important role in the pathogenesis of cGVHD.

For patients who received bone marrow or stem cells, it is estimated that 40%-70% may experience chronic GVHD.

“Steroids are currently our only standard treatment for chronic GVHD and they are often not effective,” noted senior author Stefanie Sarantopoulos, MD, PhD, assistant professor in the division of hematology/oncology and the departments of microbiology and immunology at the UNC School of Medicine. This study offers BAFF and the BAFF-mediated signaling pathways that contribute to this “revved up” B-cell activity as potentially suitable sources of novel therapeutic targets for chronic GVHD patients.

The study was published August 15, 2012, in the journal Blood.

Related Links:

University of North Carolina’s Lineberger Comprehensive Cancer Center




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.